StoneX Group’s Alaunos Therapeutics TCRT Stock Holding History

StoneX Group’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-227	Closed	-$2.4K	–	715
2023 Q4	$2.4K	Buy	+227	New	+$2.73K	﹤0.01%	585

Other funds holding TCRT

MSD Partners New York $76.8M AUM 34.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ACM

Allred Capital Management Dallas, Texas $305M AUM 26.92% 1-Year Est. Return

StoneX Group's TCRT Position: Q1 2024 in Review

StoneX Group sold out of Alaunos Therapeutics (TCRT) in Q1 2024, closing a stake of 227 shares — an estimated $2.4K sold.

StoneX Group first reported a position in TCRT in Q4 2023 and held it in 1 quarter. The position peaked at $2.4K in Q4 2023. 45 funds tracked by Wall St. Rank hold TCRT as of Q1 2024.

StoneX Group reported no remaining Alaunos Therapeutics position as of Q1 2024 after selling out during the quarter.
StoneX Group sold 227 Alaunos Therapeutics shares in Q1 2024, an estimated $2.4K.
StoneX Group first reported a position in Alaunos Therapeutics in Q4 2023 and held it in 1 quarter.
StoneX Group's Alaunos Therapeutics position peaked at $2.4K in Q4 2023.
45 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2024.

Based on StoneX Group's 13F filing for Q1 2024, filed 1 May 2024.